Goldman Sachs and EQT AB expand in the medical sector

The week begins with news about a new acquisition

Goldman Sachs Group’s investment arm and the Swedish private equity firm EQT AB revealed they would buy Parexel International – a clinical research company – from Pamplona Capital Management for $8.5 billion, including debt.

According to Bloomberg, Parexel drew interest from about ten parties, including various private-equity firms and drug distributor AmerisourceBergen. The company was founded in 1982, and it’s headed by Jamie Macdonald, a former adviser to EQT. He will remain chief executive after the deal closes.

For Goldman Sachs, this is not the first investment in the medical field. Its Asset Management oversees, among others, a manager of optometry services it purchased in 2019 and Datavant – a health care data-management company it invested in last month. The arm has roughly $2 trillion under management.

EQT oversees $79 billion in assets and focuses on real estate, technology, infrastructure, and healthcare.

Source: thestreet.com